Aarti Drugs shares staged a dramatic recovery on Tuesday, surging 11.12% and breaking an eight-day losing streak. The stock, which opened at ₹425.95 after Monday’s close at ₹423.95, remained flat through most of the session. But a late-hour rally saw it skyrocket to an intraday high of ₹495.55 before settling at ₹471.10, making it the top gainer among group A stocks. The surge came on the heels of an announcement that Aarti Drugs received an Establishment Inspection Report (EIR) from the USFDA for its API manufacturing facility in Tarapur, Maharashtra. The report confirmed that the facility, which produces key APIs like Ciprofloxacin HCl, Zolpidem Tartrate, and Celecoxib, is classified as “voluntary action indicated” (VAI). This rating signifies minimal compliance issues and clears the way for exports to the lucrative US market. Despite Tuesday’s gains, Aarti Drugs has had a tough year, with the stock down 4% year-to-date. If the upward momentum continues, December could mark the end of a prolonged losing streak.